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5. Tools of the visualization
6. How to avoid the common mistakes in analyzing the data derived 
from the high throughput assays.
Targeted audience: Researchers, Molecular Biologist, Clinical Re-
search Scientist, R&D Professionals, IT & Informatics Professionals, 
Statisticians, Bioinformaticians, and mathematicians.
Talk outline: Many of the examples of this talk are based on actual mi-
croarray gene proﬁle data as well as the matrix assisted laser desorption 
ionization time-of-ﬂight, mass spectrometry (MALDI-TOF MS) protein 
proﬁle data that I have analyzed or recently published articles. My hope 
is that the theory of the bioinformatics aspects of the examples would 
provide a springboard for the motivated audience. The topics that will 
be covered in this talk are: 
1. Introduction to the high throughput assays - today and tomorrow.
2. Issues of the experiment design of the high throughput assays.
3. Topics of the data pre-processing including the assessment of the 
quality control.
4. Methods of the data analysis: data mining, pattern recognition, class 
comparison, model prediction.
5. Tools of the visualization
The common mistakes of analyzing the data derived from the high 
throughput assays will be discussed. Several software packages such as 
Wavelet-based Project Spectrum Network (WPSN) package for mass 
spectrum data preprocessing, Weighted Flexible Compound Covariate 
Method (WFCCM) for class prediction, and Mutidimensional Scaling 
and Cluster analysis for visualization will be introduced to the audi-
ence. The goal of this talk is understanding, applying, and not misusing 
the bioinformatics tools in high dimensional data derived from high 
throughput assays.
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Lung cancer is one of the leading causes of death globally. Over the 
past two decades, signiﬁcant advances have been made in the treatment 
of non-small cell lung cancer (NSCLC). Randomized phase III studies 
continue to be the gold standard for deﬁning new standard of care. 
Phase III trials are expensive, time consuming and resource intensive. 
A vast majority (>90%)of phase III trials do not meet their endpoints. 
While the number of new compounds registered for development in 
NSCLC is higher now than ever before, the proportion of adults with 
cancer enrolled in clinical trials is dismally low. There is an urgent need 
to develop novel phase II designs and endpoints that would enable us 
to select compounds /combinations that are likely to succeed in phase 
III trials.
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Pharmacogenomics is known as the science that allows researchers to 
predict the probability of a drug response based on a person’s genetic 
makeup. For instance, it is known that patients with Gilbert’s disease 
associated with UGT1A1 polymorphism will have excessive toxicity 
with the recommended dose of irinotecan due to impaired ability of 
detoxifying the active metabolite of the drug. On the label, “Individu-
als who are homozygous for the UGT1A*28 allele are at increased risk 
for neutropenia following initiation of irinotecan treatment. A reduced 
initial dose should be considered for patients known to be homozygous 
for the UGT1A*28 allele. Heterozygous patients may be at increased 
risk of neutropenia; however clinical results have been variable and 
such patients have been shown to tolerate normal starting doses. 
Although a large amount of new data on relationship between clinical 
outcome of current therapeutic strategies and interindividual genetic 
markers are being published, clinical efﬁcacy and toxicity for the 
individual patient of particular chemotherapy agents are unpredictable 
(Lenz HJ, JCO 2004;22:2519-2521). From the statistical viewpoints, 
we can say that the prediction from UGT1A1 polymorphism to inci-
dence of some toxicity is another issue.
We recently developed a prognostic index to discriminate the risk 
groups among advanced epithelial ovarian cancer based on demo-
graphic, clinical and pathological characteristics of patients (Teramukai 
S, et al. JCO 2007, in press). Accuracy of the simple risk group model 
was statistically evaluated with respect to discrimination and calibra-
tion and reproducibility of the model was accessed by data-splitting 
method. The deﬁnitions of accuracy and generalizability with regard 
to assessment of a prognostic system have been discussed (Justice 
AC, et al. Ann Intern Med 1993;130:515-524). Accuracy (calibration 
and discrimination) is the degree to which predictions match observed 
outcomes. Generalizability (reproducibility and transportability) is the 
ability of a prognostic system to provide accurate predictions in a new 
sample of patients. Reproducibility requires the system to replicate its 
accuracy in patients who were not included in development of the sys-
tem but who are from the same underlying population. Transportability 
requires the system to produce accurate predictions in a sample drawn 
from a different but plausibly related population or in data collected 
by using slightly different methods than those used in the development 
sample. A goal of personalized medicine is to improve such a partially 
validated prognostic system incorporating genomic information, to 
evaluate reproducibility with prospective clinical trials, and to assess 
generalizability with large-scale database on clinical practice.
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Introduction: Our immune system is our body’s natural defense 
mechanism and consists of two types of immune responses, innate vs 
adaptive. Although our immune system is effective in defending against 
infectious diseases, it appears ineffective in defending against a cancer 
once it has been established in the body. Two widely accepted reasons 
that manipulation of the immune system for cancer treatment has been 
unsuccessful are that cancer is not immunogenic and that the cancer 
microenvironment can suppress the immune system. The purpose of 
cancer vaccine or immunotherapy is to elicit a more powerful active 
immunity, either antibody-mediated or cell-mediated, from patients 
to overcome these two barriers to development of therapeutic cancer 
immunity.
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Cancer vaccine refers to an intervention whereby a person’s immune 
system is coaxed into recognizing and destroying malignant cells and 
is generally considered an immunotherapy as it is therapeutic rather 
than prophylactic. The challenge in design of clinical trials of cancer 
vaccines and immunotherapy is to demonstrate a therapeutic effect on 
an established cancer with an immune-based intervention rather than 
prevent the development of cancer. 
In this presentation we will attempt to describe issues in design of 
clinical trials in cancer vaccines and immunotherapy and illustrate them 
using recent vaccine trials in lung cancer.
Design Issues: The patient population suitable for vaccine and im-
munotherapy trials requires careful consideration. New cytotoxic or 
molecularly targeted agents are traditionally tested on advanced and 
heavily pretreated cancer patients. Seriously ill patients are unlikely to 
have the functioning immune systems required for an effective vaccine 
strategy. Additionally, cancer vaccines may not be effective against 
advanced tumor burden. A more appropriate patient population would 
be individuals with minimal residual disease where previous treatment 
such as surgical resection or radical radiotherapy (with or without sys-
temic treatment) has treated all macroscopic disease but risk of relapse 
from microscopic residual disease is high. Because some of the patient 
population may be cured by primary therapy, the sample size estimation 
in vaccine trials may be different from chemotherapy trials of advanced 
cancer where all patients are potential beneﬁciaries of treatment. The 
patient populaton with minimal residual disease would be expected to 
have fewer recurrence and fatal events requiring a larger sample size 
to declare a difference statistically signiﬁcant. These trials also require 
longer follow-up and are therefore more expensive than interventions 
for advanced disease where events occur quickly. 
Clinical trials in cancer vaccine and immunotherapy are also catego-
rized into different phases, but they are not as clearly delineated as in 
clinical trials of chemotherapy. 
Phase I trials in cancer vaccines are small, typically enrolling no more 
than 30-50 patients, rather than healthy volunteers. Unlike clinical trials 
in chemotherapy, they may be double-blind, placebo-controlled trials 
with different doses and schedules. The objective of phase I clinical 
trials in cancer vaccines is primarily to evaluate clinical safety and 
tolerability, but secondarily it is also to obtain preliminary assessments 
of immunogenicity. Generally, adverse events from vaccine trials are 
limited to swelling, tenderness and redness at the injection site. As in 
prophylactic vaccines, systemic reactions such as fevers or muscle 
aches, are also fairly common for most cancer vaccines. Phase I vac-
cine trials typically involve several dose levels to investigate whether 
a higher dose of the vaccine is as immunogenic as a lower dose. Quan-
tiﬁcation of a dose-response relationship identifys the smallest dose 
that provides adequate immunogenicity, oftentimes designated as the 
minimum effective dose.
After the minimum effective does is identiﬁed, immunogenicity, safety 
and tolerability of the vaccine are investigated further in phase II trials. 
Unlike chemotherapy trials, where drug activity may be identiﬁed by 
tumor regression, response rates for many vaccine studies are low or 
nonexistent. The efﬁcacy of the vaccine must be identiﬁed by other 
endpoints including time-to-progression or survival. If the patient 
population is selected for minimal residual disease from previous 
therapy, it is difﬁcult to estimate the median time- to-progression and 
median survival times in a pilot project. This difﬁculty in estimating 
outcome, together with the infrequency of responses, make single arm 
phase II studies difﬁcult to interpret. A randomized phase II design with 
a control group not receiving the vaccine therapy may provide a better 
signal of potential beneﬁt warranting a phase III trial. 
In a phase III trial, the primary endpoint should be overall survival 
and time to disease progression. Vaccination is a treatment well suited 
for double-blind placebo controlled design. In phase II/III trials, the 
primary objective is to evaluate the efﬁcacy but also to assess whether 
the biomarkers of immunogenicity are correlated with clinical efﬁcacy 
endpoints, namely, the surrogacy of immunogenicity for clinical 
outcome. In that regard there is some similarity with clinical trials with 
molecularly targeted therapy. 
Examples: In a randomized phase IIB trial of BLP25 liposome vaccine 
(L-BLP25), patients with stage IIIB-IV non-small cell lung cancer were 
randomized to receive either L-BLP25 plus best supportive care (BSC) 
or BSC alone stratiﬁed by disease status, stage IIIB locoregional (LR) 
vs stage IIIB with malignant pleural effusion and stage IV. Patients 
randomized to L-BLP25 plus BSC were given primary treatment 
consisting of a single low dose of cyclophosphamide 3 days before the 
ﬁrst L-BLP25 vaccination, followed by eight weekly subcutaneous 
vaccinations of 1,000 μg of L-BLP25 administered at weeks 0-7. The 
primary efﬁcacy endpoint of the trial was overall survival. The sample 
size estimation (a total of 108 deaths from 166 patients assuming 10% 
dropout rate) was based on detecting a difference in median survival of 
5 months (7 months for the BSC arm and 12 months for the L-BLP25 
arm for a hazard ratio of 0.583) with a power of 0.80 at a one-sided 
level 0.025 log-rank test. Notably, the patients with metastatic disease 
appeared to have no beneﬁt from the vaccine but a stratiﬁed subset 
of stage III patients that presumably had less residual disease had an 
interesting trend for superior survival that has resulted in the initiation 
of a phase III trial that will include more than 1000 patients. Essentially 
the experimental design of this vaccine trial in lung cancer was not very 
different from that of chemotherapy trials.
In a randomized, double-blind, placebo-controlled phase II trial of the 
MAGE-A3 vaccination (recombinant MAGE-A3 protein and a potent 
GSK immunological adjuvant), patients with completely resected, 
MAGE-A3 positive (assessed by quantitative rt-PCR), stage IB or 
II NSCLC were randomized in a 2:1 ratio to receive post-operative 
MAGE-A3 vaccination or placebo, stratiﬁed by stage (IB vs II), histol-
ogy (squamous vs other), and lymph node procedure (sampling vs 
dissection). Vaccination was started ≥ 6 weeks after surgery, with ﬁve 
vaccinations at 3-week intervals, followed by eight vaccinations every 
3 months, and other anti-cancer adjuvant therapy was not allowed. The 
primary efﬁcacy endpoint was time to recurrence. A sample size of 180 
patients (120 active and 60 placebo) was chosen to achieve a power 
of 0.48 to detect a 10% difference in the recurrence rate at month 30 
at a two-sided level 0.10 log-rank test from a 40% recurrence rate on 
placebo assuming a 20% dropout rate. Again the experimental design 
of this vaccine trial was not different from that of chemotherapy trials.
Conclusion: Despite the progress that has been made and the lessons 
that have been learned over the years, there are still basic questions 
about how to get the most out of the immune system using therapeutic 
vaccines and immunotherapy. With generation of more sophisticated 
knowledge about the immune system and composition of vaccines, we 
may be poised to enter the era of clinically effective cancer vaccines. A 
long history of vaccine and immunotherapy failure in cancer medicine 
has generated much skepticism. Attention to detail in clinical trial 
design is crucial for convincing proof of efﬁcacy. 
